Burns - Pipeline Review, H2 2018

Burns - Pipeline Review, H2 2018


  • Products Id :- GMDHC10737IDB
  • |
  • Pages: 87
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Burns-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns-Pipeline Review, H2 2018, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 3, 2, 11, 3 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).

- The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Burns-Overview

Burns-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Burns-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Burns-Companies Involved in Therapeutics Development

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

CFM Pharma Holding BV

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

Madam Therapeutics BV

MallInckrodt Plc

MediWound Ltd

Phagelux Inc

Se-cure Pharmaceuticals Ltd

Therapure Biopharma Inc

USV Pvt Ltd

Burns-Drug Profiles

(cerium nitrate hexahydrate + silver sulfadiazine)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(chlorpheniramine maleate + ibuprofen)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGLE-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

albumin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BH-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bromelains-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Dermatology and Immunology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENERGIF-711-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epidermal growth factor biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISN-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neu-2000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NJ-01SS-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligomer G for Burn Wounds-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and Musculoskeletal Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrvinium pamoate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize EPCR for Wounds and Burns-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAAP-148-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-106-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0125-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silver sulfadiazine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Burns-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Bacterial Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vanadis-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XF-70-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burns-Dormant Projects

Burns-Discontinued Products

Burns-Product Development Milestones

Featured News & Press Releases

Jul 18, 2018: U.S. FDA designates Mallinckrodt's StrataGraft as regenerative medicine advanced therapy

Jun 19, 2018: MediWound Expands Its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.

Jun 11, 2018: MediWound Completes Enrollment in NexoBrid U.S. Phase 3 DETECT Study

Jun 04, 2018: NexoBrid Receives Marketing Authorization From South Koreas Ministry of Health

Apr 09, 2018: MediWound's NexoBrid to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago

Jan 23, 2018: Amarantus Subsidiary Cutanogen Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Jan 04, 2018: Amarantus Subsidiary Cutanogen Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Oct 31, 2017: NeoMatrix Therapeutics Enters Clinical Stage as Investigational New Drug Application for NMT-cP12 Goes Into Effect

Sep 11, 2017: MediWound's NexoBrid Wins Best Poster Presentation Award at the 17th European Burns Association Congress

Sep 06, 2017: MediWounds NexoBrid Highlighted in 43 Presentations at the 17th European Burns Association Congress

Jul 19, 2017: BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid Indications

Jun 23, 2017: BARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWound's NexoBrid Development

Jun 16, 2017: Independent Study in Germany Shows NexoBrid Reduces Average Burn Treatment Costs by nearly 30% Versus Standard of Care

Jun 02, 2017: Poster Presentation Highlighting NexoBrid Awarded "Best Poster" at the 52nd Congress of the Spanish Society of Aesthetic, Plastic and Reconstructive Surgery

Apr 04, 2017: Madam Therapeutics Announces US patent No. 9,562,085 grant for SAAP-10

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Burns, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Burns, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Burns-Pipeline by AlgiPharma AS, H2 2018

Burns-Pipeline by Alliance Pharma Plc, H2 2018

Burns-Pipeline by Amarantus Bioscience Holdings Inc, H2 2018

Burns-Pipeline by CFM Pharma Holding BV, H2 2018

Burns-Pipeline by Destiny Pharma Plc, H2 2018

Burns-Pipeline by Energenesis Biomedical Co Ltd, H2 2018

Burns-Pipeline by Madam Therapeutics BV, H2 2018

Burns-Pipeline by MallInckrodt Plc, H2 2018

Burns-Pipeline by MediWound Ltd, H2 2018

Burns-Pipeline by Phagelux Inc, H2 2018

Burns-Pipeline by Se-cure Pharmaceuticals Ltd, H2 2018

Burns-Pipeline by Therapure Biopharma Inc, H2 2018

Burns-Pipeline by USV Pvt Ltd, H2 2018

Burns-Dormant Projects, H2 2018

Burns-Dormant Projects, H2 2018 (Contd..1), H2 2018

Burns-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

CFM Pharma Holding BV

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

Madam Therapeutics BV

MallInckrodt Plc

MediWound Ltd

Phagelux Inc

Se-cure Pharmaceuticals Ltd

Therapure Biopharma Inc

USV Pvt Ltd

Burns Therapeutic Products under Development, Key Players in Burns Therapeutics, Burns Pipeline Overview, Burns Pipeline, Burns Pipeline Assessment

select a license
Single User License
USD 2000 INR 142660
Site License
USD 4000 INR 285320
Corporate User License
USD 6000 INR 427980

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com